Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I, Randomized, Parallel Group Study to Evaluate the Effect of Multiple Oral Doses of Eurartesim on the QT/QTc Interval Compared to Riamet, Placebo and Moxifloxacin in Healthy Male and Female Volunteers.

Next Previous
Trial Profile

Phase I, Randomized, Parallel Group Study to Evaluate the Effect of Multiple Oral Doses of Eurartesim on the QT/QTc Interval Compared to Riamet, Placebo and Moxifloxacin in Healthy Male and Female Volunteers.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 23 Nov 2011

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dihydroartemisinin/piperaquine (Primary) ; Artemether/lumefantrine; Moxifloxacin
  • Indications Acute exacerbations of chronic bronchitis; Acute sinusitis; Bacterial infections; Malaria; Respiratory tract infections; Skin and soft tissue infections; Tuberculosis
  • Focus Adverse reactions

    • Most Recent Events

    • 16 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Jun 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
    • 19 Apr 2010 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top